CD8A and neoplasm: CB-1158 could block myeloid cell-mediated inhibition of T cell proliferation, increase the number of tumor-infiltrating CD8+ T cells and NK cells, and increase the expression of inflammatory factors and interferon-α, thereby changing the immune microenvironment to promote inflammation and reduce tumor immune escape, inhibiting tumor cell proliferation.190